Sangamo BioSciences Inc (SGMO)

3.00
NASDAQ : Health Care
Prev Close 3.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.90 / 9.83
Avg Volume 898.70K
Exchange NASDAQ
Shares Outstanding 70.62M
Market Cap 218.93M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Sangamo's Genome Editing Program For Hemoglobinopathies To Transfer To Biogen's Spin-Off Bioverativ

Sangamo's Genome Editing Program For Hemoglobinopathies To Transfer To Biogen's Spin-Off Bioverativ

ZFN-Mediated Genome Editing Programs in Sickle Cell Disease and Beta-Thalassemia Will Move from Biogen to Bioverativ in Line with the Spin-Off Company's Focus on Rare Blood Disorders

Short Interest Expands By 11.8% For SGMO

Short Interest Expands By 11.8% For SGMO

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 918,730 share increase in total short interest for Sangamo BioSciences Inc , to 8,679,778, an increase of 11.84% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Shares of Omeros fell almost 10% after analysts' downgraded the biotech.

Short Interest Falls 12.2% For SGMO

Short Interest Falls 12.2% For SGMO

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,057,847 share decrease in total short interest for Sangamo BioSciences Inc , to 7,636,100, a decrease of 12.17% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program For Treatment Of Hemophilia A

Scientists Present Preclinical Data Demonstrating High Levels of Factor VIII Protein Expression from Proprietary Therapeutic AAV cDNA Construct at World Federation of Hemophilia 2016 World Congress

First Week of SGMO February 2017 Options Trading

First Week of SGMO February 2017 Options Trading

Investors in Sangamo BioSciences Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS II

Company Advances Third In Vivo Protein Replacement Platform™ (IVPRP) Program into Clinical Development

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor

Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

Sangamo BioSciences Presents Recent Developments From Research And ZFP Therapeutic® Programs In Multiple Presentations At Annual Meeting Of The American Society Of Gene And Cell Therapy

New Histologic Data Demonstrate Disease Correction in Tissues after ZFP Therapeutic Treatment in Mouse Model of MPS I

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Today's Weak On High Volume Stock: Sangamo BioSciences (SGMO)

Trade-Ideas LLC identified Sangamo BioSciences (SGMO) as a weak on high relative volume candidate

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Commit To Buy Sangamo BioSciences At $5, Earn 23% Using Options

Investors considering a purchase of Sangamo BioSciences Inc shares, but tentative about paying the going market price of $6.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.15.

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

7 Stocks Under $10 to Trade for Breakout Gains

7 Stocks Under $10 to Trade for Breakout Gains

These stocks trading for less than $10 a share are within range of triggering big breakout trades.